key: cord-0720313-71p7v8mt
authors: Criado, P.R.; Ianhez, M.; Rocha, P.S.; Miot, H.A.
title: Pityriasis rubra pilaris (type I) following ChAdOx1 COVID‐19 vaccine: A report of two cases with successful treatment with oral isotretinoin
date: 2022-03-15
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.18055
sha: a16721174b99dc4735800f25e4e67ae704bb7125
doc_id: 720313
cord_uid: 71p7v8mt

nan

progressed to dorsum, upper and lower limbs. There was no history of drug intake, except losartan 50 mg QD for systemic arterial hypertension during the past four years. Histopathological analysis was compatible with pityriasis rubra pilaris (Fig. 1d) . The patient was treated with isotretinoin 30 mg QD and emollients for three months with total remission. Case 2; A 42-year-old man was vaccinated with two doses of AstraZeneca vaccine, without intercurrences. After 8 days of the second dose, scaly reddish plaques were observed on his face and then progressed all over the body in one week, leaving healthy skin areas, especially on the trunk, with a citrine colour (Fig. 1c) , without nail involvement or palmoplantar hyperkeratosis. There was no history of drug intake or comorbidities. The histopathological analysis was analogous to the first case ( Fig. 1d) and he was treated with isotretinoin 40mg/day in two months with partial clearance and then, 20mg/day in the third month with mild erythema.

The causal relationship between COVID-19 vaccines and cutaneous immunological reactions is still not understood, but they can be due to an upregulated inflammatory immunological pathway or cross-reactivity between vital or adjuvant molecules and self-antigens. 4 Familiar cases of PRP revealed gain of function at CARD14 gene, which codifies the scaffold protein CARMA2, leading to the activation of (NF-jB) by the complex CARMA2-BCL10-MALT1. As long as CARD14 can be induced by IL17 and PAMPS, inflammatory and infectious stimuli are thought to elicit PRP in genetically predisposed individuals. 1 The seven patients who developed PRP after COVID-19 vaccination are listed at the Table 1 . Their age varied from 31 to 82 years, both sexes were affected and different types of PRP have been presented. [3] [4] [5] [6] Four patients presented the onset of adverse reactions in a mean time of 13 days after the first dose, 3-5 one presented flare after the first and second dose 6 and two of them after a medium of 6,5 days after the second dose. 3 Four patients (57.14%) received (AstraZeneca), 4,5 one (14.28%) mRNA-1273 (Moderna) 3 and two (28,58%) BNT16B2b2 (BioNTech/Pfizer). 3, 6 Despite the PRP might be, in most cases, persistent, 7 in these series patients seem to improve mostly with retinoids but also with oral and topical corticosteroids. [3] [4] [5] [6] The majority of cases occurred after the first dose, 3-6 but one had resolved prior to the second dose and there was no recurrence. 4 These reactions occur in a close range of time (≤15 days), suggesting a pattern that could be linked to vaccination. 3 PRP can be elicited by COVID-19 vaccination. [2] [3] [4] [5] [6] Clinicians must be aware of this adverse event, probably facilitated by a genetic background, but prone to respond to treatment with a good prognosis. 

Familial pityriasis rubra pilaris is caused by mutations in CARD14

Pityriasis rubra pilaris occurring after vaccination with diphtheria-pertussis-tetanus and oral poliovirus vaccines

Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine

An old entity, a new trigger: post COVID-19 vaccine pityriasis rubra pilaris

Pityriasis rubra pilaris after Vaxzevria â COVID-19 vaccine

Pityriasis rubra pilarislike eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine

A review on pityriasis rubra pilaris